TL;DR
This study reveals that elevated levels of a systemic inflammation marker, Glycoprotein acetyls (GlycA), are linked to brain atrophy and cognitive decline in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Specifically, higher GlycA levels predict future cognitive decline and brain volume loss, particularly in those with late MCI, suggesting GlycA could be a valuable biomarker for early detection and intervention strategies.
What Problem Does This Paper Address?
Alzheimer's disease (AD) is a devastating neurodegenerative disorder, and while inflammation is known to play a role, the precise mechanisms and how peripheral inflammation impacts the brain remain complex. Researchers are seeking reliable biomarkers to track disease progression and identify individuals at risk. Previous studies have hinted at a connection between systemic inflammation and AD, but a comprehensive evaluation of how a specific inflammatory marker, Glycoprotein acetyls (GlycA), relates to various aspects of AD pathology – including brain structure and cognitive function over time – was lacking. This paper aims to fill that gap by investigating the association between GlycA levels and AD-related biomarkers in a large cohort, exploring its predictive power for cognitive decline and brain atrophy.
Methods
The researchers utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, a well-established longitudinal study of aging and dementia.
- GlycA Measurement: Plasma GlycA levels were quantified using nuclear magnetic resonance (NMR) spectroscopy via the Nightingale Health platform. This method is noted for its reduced biological variability compared to other inflammatory markers like C-reactive protein (CRP).
- Cognitive Assessments: Standardized composite scores for executive function (EF) and memory (MEM) were used, derived from various cognitive tests.
- Neuroimaging: Magnetic Resonance Imaging (MRI) was used to measure brain volumes, specifically focusing on regional atrophy.
- Statistical Analysis:
- Cross-sectional analysis: Spearman's correlation was employed to assess relationships between GlycA and brain/cognitive measures at a single time point.
- Longitudinal analysis: Linear mixed-effects models and Spearman's correlation were used to evaluate how baseline GlycA levels predicted future changes in cognitive function and brain volumes over several years.
- Stratification: Analyses were stratified by diagnosis status (cognitively normal, MCI subtypes, AD) and sex to understand how these factors influence the observed associations.
- Covariate Adjustment: GlycA levels and other measurements were adjusted for potential confounders such as age, sex, BMI, education, APOE genotype, and medication use.
Datasets
The study primarily used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, which includes a large number of participants (n=1506) with comprehensive demographic, clinical, cognitive, neuroimaging, and biomarker data collected longitudinally. No new datasets were introduced.
Key Insights and Ideas
- GlycA as a Systemic Inflammation Indicator: The study reinforces GlycA's role as a reliable indicator of systemic inflammation, showing it's elevated in individuals with AD compared to cognitively normal participants.
- Peripheral Inflammation's Impact on the Brain: The core insight is that peripheral inflammation, as measured by GlycA, is not just a bystander but actively contributes to neurodegeneration and cognitive decline in AD.
- The Critical Role of MCI Stage: The findings highlight that the stage of mild cognitive impairment (specifically late MCI or LMCI) is crucial. Individuals with LMCI at baseline showed the most pronounced associations between GlycA and future cognitive decline and brain atrophy, suggesting this stage might be a critical window for intervention.
- Sex Differences in Cross-sectional Associations: While longitudinal associations were not sex-dependent, cross-sectional analyses revealed that GlycA correlated with brain atrophy more significantly in females with LMCI and AD, suggesting potential sex-specific vulnerabilities to inflammation's structural impact on the brain.
Key Results
- Elevated GlycA in AD: GlycA levels were significantly higher in participants with AD compared to cognitively normal (CN), significant memory concern (SMC), and early mild cognitive impairment (EMCI) groups.
- GlycA Predicts Future Cognitive Decline: In participants diagnosed with LMCI at baseline, higher baseline GlycA levels were associated with a future decrease in executive function over 3-9 years. Similar, though weaker, trends were observed for memory decline.
- GlycA Predicts Future Brain Atrophy: Baseline GlycA levels were also associated with a future decrease in entorhinal cortex volume in participants with LMCI at baseline, observed over several years.
- Cross-sectional Brain Atrophy in Females: In females diagnosed with LMCI or AD, GlycA correlated negatively with several regional brain volumes, including frontal lobe, cerebral cortex grey matter, and hippocampus. These associations were largely specific to females.
- No Link to CSF A/T/N Biomarkers: Interestingly, plasma GlycA levels did not show a significant association with core AD cerebrospinal fluid (CSF) biomarkers like amyloid-beta (Aβ) and tau.
Limitations and Future Work
- Observational Nature: The study is observational, meaning it can identify associations but cannot definitively prove causation.
- Sample Size in Stratified Analyses: Some stratified analyses, particularly for the SMC group, involved relatively small sample sizes, which could limit statistical power.
- Comorbidity: The study did not deeply explore the impact of co-occurring inflammatory diseases (like diabetes) on the GlycA-AD relationship, although GlycA is considered a general marker of systemic inflammation.
- Future Directions: The authors suggest further longitudinal studies on aged models and populations with chronic inflammation to clarify sex-specific effects. They also emphasize the need for replication in independent cohorts and exploring the potential of GlycA as a biomarker for personalized therapeutic interventions, particularly in the LMCI stage. Investigating other cognitive domains not covered in this study is also suggested.
Summary updated